Why is Natco Pharma Ltd. falling/rising?

Recent Price Movement and Market Context

Natco Pharma’s stock price surged by ₹60.45 on 16 February, reaching an intraday high of ₹931.9, reflecting a strong intraday rally of 13.36%. This sharp upward movement came after a brief period of consecutive falls, signalling a trend reversal that caught the attention of investors. The stock outperformed the broader sector and the Sensex benchmark, which declined by 0.94% over the past week, while Natco Pharma gained 4.43% in the same period. Over the past month, the stock also posted a positive return of 2.62%, contrasting with the Sensex’s marginal decline of 0.35%. Despite this recent strength, the stock remains slightly down year-to-date by 2.32%, closely mirroring the Sensex’s 2.28% fall.

Notably, Natco Pharma has demonstrated robust long-term performance, with a three-year return of 64.21%, nearly doubling the Sensex’s 35.81% gain. However, over five years, the stock’s 7.54% return lags behind the Sensex’s 59.83%, indicating some volatility and mixed investor sentiment over extended periods.

Fundamental Strengths Supporting the Rally

Several fundamental factors underpin the recent price appreciation. Natco Pharma boasts a high return on equity (ROE) of 16.25%, reflecting efficient management and effective utilisation of shareholder capital. The company maintains a conservative capital structure with an average debt-to-equity ratio of zero, reducing financial risk and appealing to risk-averse investors. Additionally, the stock trades at a reasonable valuation with a price-to-book value of 1.8, suggesting it is fairly valued relative to its peers and historical averages.

Institutional investors hold a significant 20.55% stake in Natco Pharma, and their holdings have increased by 0.59% over the previous quarter. This rise in institutional participation often signals confidence in the company’s prospects, as these investors typically conduct thorough fundamental analysis before committing capital.

Challenges Tempering Investor Optimism

Despite the recent price rally, Natco Pharma faces significant headwinds. The company reported disappointing quarterly results for December 2025, with net sales plummeting 41.0% compared to the average of the previous four quarters. Profit before tax (excluding other income) declined sharply by 71.6%, and net profit after tax fell by 60.6% over the same period. These steep declines in core financial metrics have understandably raised concerns among investors about the company’s near-term earnings trajectory.

Moreover, the stock has underperformed the broader market over the past year. While the BSE500 index generated returns of 13.31% during this period, Natco Pharma’s stock delivered a marginal negative return of 0.13%. This underperformance, coupled with a 16.5% drop in profits over the last year, suggests that the company is grappling with operational challenges that have yet to be fully resolved.

From a trading perspective, although the stock is currently trading above its key moving averages (5-day, 20-day, 50-day, 100-day, and 200-day), indicating a positive technical trend, investor participation has waned slightly. Delivery volumes on 13 February fell by 4.11% compared to the five-day average, signalling some caution among market participants despite the price gains. The stock remains sufficiently liquid, with a trade size capacity of approximately ₹1.24 crore based on recent average traded values.

Conclusion: A Stock in Recovery but Facing Headwinds

Natco Pharma’s recent price rise on 16 February reflects a short-term rebound driven by positive technical signals, strong management efficiency, and increased institutional interest. The stock’s outperformance relative to its sector and the broader market over the past week and month underscores renewed investor confidence. However, the company’s weak quarterly financial results and underperformance over the past year highlight ongoing challenges that may temper enthusiasm.

Investors should weigh the company’s attractive valuation and solid return on equity against the significant profit declines and cautious investor participation. While the stock shows signs of momentum, the mixed fundamental backdrop suggests that a cautious approach remains prudent until clearer evidence of sustained earnings recovery emerges.

Get 2 full years of MojoOne Premium for only Rs. 12,999. Subscribe for 1 year and we'll add another year FREE. Offer valid for a limited time. Start Saving Now →